Bone Therapeutics S.A
11
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
36.4%
4 terminated/withdrawn out of 11 trials
60.0%
-26.5% vs industry average
18%
2 trials in Phase 3/4
50%
3 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head
Role: lead
Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis
Role: lead
A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis
Role: lead
Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures
Role: lead
Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture
Role: lead
Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal Fusion
Role: lead
Research Study on the Immunosuppressive Effects of a Cell Therapy Product on PBMC Isolated From Blood of Patients With Inflammatory Rheumatic Diseases
Role: lead
Study on Allogeneic Osteoblastic Cells Implantation in Rescue Interbody Fusion
Role: lead
A mRUS Validation Study for Nail-treated Fractures of Long Bones and a TUS Exploratory Study for Nail and Plate-treated Fractures of Long Bones
Role: lead
Study on Autologous Osteoblastic Cells Implantation in Hypotrophic Non-Union Fractures
Role: lead
Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head
Role: collaborator
All 11 trials loaded